medicine Product List and Ranking from 6 Manufacturers, Suppliers and Companies | IPROS

Last Updated： Aggregation Period:Jan 14, 2026～Feb 10, 2026
This ranking is based on the number of page views on our site.

medicine Manufacturer, Suppliers and Company Rankings

Last Updated： Aggregation Period:Jan 14, 2026～Feb 10, 2026
This ranking is based on the number of page views on our site.

  1. 日本工機 高機能品営業部 Tokyo//Building materials, supplies and fixtures manufacturers
  2. Tohoku Techno Arch Co., Ltd. Miyagi//Educational and Research Institutions
  3. null/null
  4. 4 エクシィズ Gifu//Building materials, supplies and fixtures manufacturers
  5. 4 エヌ・ティー・エス Tokyo//Service Industry
Go to Company Ranking

medicine Product ranking

Last Updated： Aggregation Period:Jan 14, 2026～Feb 10, 2026
This ranking is based on the number of page views on our site.

  1. Non-explosive, low-vibration steam pressure crushing agent 'Gunsizer' 日本工機 高機能品営業部
  2. Tohoku Univ. Technology ：Lubiprostone, a constipation drug, has a kidney protective effect：T25-005 Tohoku Techno Arch Co., Ltd.
  3. Science of Ceramics 3: Pursuing Beauty in Glazes
  4. Tile glaze: production, types, differences *Technical materials available エクシィズ
  5. 4 Tohoku University Technology: Treatment Drug for BRAF Mutant Cancer: T21-052 Tohoku Techno Arch Co., Ltd.

medicine Product List

1～27 item / All 27 items

Displayed results
Tile glaze: production, types, differences *Technical materials available

Tile glaze: production, types, differences *Technical materials available

Free technical materials explaining the glaze of tiles, including production, types, differences, etc.

The 'Tile Glaze: Production, Types, and Differences' is a technical document that explains the production, types, and differences of tile glazes. We provide know-how that only the tile professionals at 'Exys' can understand. [Contents (a partial introduction)] ■ What is glaze? ■ How is it made? ■ What types are available? ■ Differences in the number of glaze applications and surface conditions, etc. *For more details, please refer to the PDF available for download.

  • Tile/indoor/outdoor
  • tile
  • Interior and exterior tiles
  • medicine

Added to bookmarks

Bookmarks list

Bookmark has been removed

Bookmarks list

You can't add any more bookmarks

By registering as a member, you can increase the number of bookmarks you can save and organize them with labels.

Free membership registration
Tohoku University Technology: Treatment Drug for BRAF Mutant Cancer: T21-052

Tohoku University Technology: Treatment Drug for BRAF Mutant Cancer: T21-052

BRAFV600E mutation cancer treatment agent

The BRAFV600E mutation is observed in multiple cancer types and is associated with a poor prognosis compared to other molecular subtypes. In the treatment of BRAF-mutant colorectal cancer patients, molecular targeted therapies have been developed, including combination therapies of BRAF inhibitors with anti-EGFR antibody drugs, as well as a three-drug combination therapy of BRAF inhibitors, MEK inhibitors, and anti-EGFR antibody drugs, which were clinically introduced in 2020. However, BRAF-mutant colorectal cancer still has a poor prognosis, and further effective treatment strategies are needed. Therefore, this invention proposes that retinoid receptor (particularly RARα or RXRα) agonists can enhance treatment effects or overcome acquired resistance in combination therapies of BRAF inhibitors with anti-EGFR antibody drugs or BRAF inhibitors, MEK inhibitors, and anti-EGFR antibody drugs, potentially serving as an effective treatment strategy for cancers with BRAFV600E, particularly colorectal cancer.

  • others
  • medicine

Added to bookmarks

Bookmarks list

Bookmark has been removed

Bookmarks list

You can't add any more bookmarks

By registering as a member, you can increase the number of bookmarks you can save and organize them with labels.

Free membership registration
Tohoku Univ. Technology ：Amyloid‑β–Degrading Enzymes Derived from Habu Snake Venom：T23-051

Tohoku Univ. Technology ：Amyloid‑β–Degrading Enzymes Derived from Habu Snake Venom：T23-051

A Highly Selective Amyloid‑β Degrader as a Seed for Alzheimer’s Disease Therapeutics

Current Alzheimer’s disease therapies provide only limited cognitive benefit, and there is an unmet need for disease‑modifying drugs that directly reduce amyloid‑β (Aβ) accumulation.​ The inventors identified habu snake (Protobothrops flavoviridis) venom metalloproteinases (SVMPs), evolutionarily related to non‑amyloidogenic APP‑processing ADAM proteases, as potent Aβ‑degrading enzymes.​ In vitro, an SVMP cocktail cleaved secreted Aβ at the APP α‑cleavage–equivalent site, converted it to non‑toxic p3 fragments, and reduced Aβ levels in culture medium by about 90%.​ Among these, the flavoridin‑precursor–derived SVMP targets both monomeric and aggregated Aβ and shows higher substrate selectivity than neprilysin with minimal neuropeptide degradation, supporting its potential as a low‑toxicity, disease‑modifying AD drug lead.

  • others
  • medicine

Added to bookmarks

Bookmarks list

Bookmark has been removed

Bookmarks list

You can't add any more bookmarks

By registering as a member, you can increase the number of bookmarks you can save and organize them with labels.

Free membership registration
Innovative AI drug discovery

Innovative AI drug discovery

What does the fusion of medical big data and AI (artificial intelligence) bring to the field of drug discovery? A detailed explanation of the current state and challenges of innovative drug discovery technologies!

Exploring the potential of AI drug discovery through the initiatives of pharmaceutical companies, starting with large-scale projects!

  • Big Data
  • Database
  • medicine

Added to bookmarks

Bookmarks list

Bookmark has been removed

Bookmarks list

You can't add any more bookmarks

By registering as a member, you can increase the number of bookmarks you can save and organize them with labels.

Free membership registration
Hirosaki University Technology: Triptansulin Derivative: K23-010

Hirosaki University Technology: Triptansulin Derivative: K23-010

Fluorescent dyes that can be widely used from biological systems to metals.

Triptanslin is known as an antibacterial agent extracted from the plant indigo. The inventors of this invention chemically synthesized triptanslin derivatives that cannot be obtained from natural sources and were investigating the structure-activity relationship regarding antibacterial properties when they discovered that introducing an amino group at the 2-position of triptanslin resulted in strong fluorescence. This invention relates to fluorescent reagents of triptanslin. **Characteristics of Triptanslin Derivatives** - 2-Aminotryptanslin (T2NH2) can be excited in the visible light wavelength range with minimal damage to cells and changes its fluorescence color in response to the surrounding environment (polarity). Additionally, through fluorescence resonance energy transfer (FRET) with pyrene, red fluorescence derived from T2NH2 is observed when FRET-on occurs, but in the presence of certain metal ions such as mercury, it becomes FRET-off and changes to blue fluorescence derived from pyrene. - 2-Hydroxytriptanslin emits light in the wavelength range of the biological window (650-900 nm), which has excellent biocompatibility with minimal influence from proton dissociation in the excited state and absorption by water or biological substances.

  • others
  • medicine

Added to bookmarks

Bookmarks list

Bookmark has been removed

Bookmarks list

You can't add any more bookmarks

By registering as a member, you can increase the number of bookmarks you can save and organize them with labels.

Free membership registration
Tohoku University Technology: Pharmaceutical Composition for the Prevention or Treatment of Fibrosis: T10-134

Tohoku University Technology: Pharmaceutical Composition for the Prevention or Treatment of Fibrosis: T10-134

Suppress the onset and progression of pulmonary fibrosis!!

Pulmonary fibrosis is a disease in which the lungs become fibrotic, shrink, and lose function, leading to inadequate gas exchange. As pulmonary fibrosis progresses, it ultimately results in respiratory distress and can be fatal. There are currently no effective drugs or treatments established for this disease, and the survival period for affected patients is said to be 2 to 3 years. The inventor of this invention has discovered that stanniocalcin 1 (STC1), a hormone in the body, has an inhibitory effect on the onset and progression of pulmonary fibrosis. STC1 is thought to exhibit anti-fibrotic effects by reducing endoplasmic reticulum stress, which is one of the causes of fibrosis, and the associated production of TGF-β1.

  • others
  • medicine

Added to bookmarks

Bookmarks list

Bookmark has been removed

Bookmarks list

You can't add any more bookmarks

By registering as a member, you can increase the number of bookmarks you can save and organize them with labels.

Free membership registration
Tohoku University Technology: Organ Fibrosis Inhibitor: T13-204

Tohoku University Technology: Organ Fibrosis Inhibitor: T13-204

Confirmed the effects of fibrosis and inflammation improvement in a kidney fibrosis model mouse!

When the kidneys are damaged for some reason, it is known that inflammation and fibrosis can occur. As symptoms progress, renal failure can develop, necessitating regular dialysis. Dialysis is a significant burden for patients, and there is a desire for the development of therapeutic drugs that can delay the initiation of dialysis. The inventors of this invention have discovered compounds with anti-inflammatory and anti-fibrotic effects. The group of compounds in this invention is expected to be useful as fibrosis inhibitors.

  • others
  • medicine

Added to bookmarks

Bookmarks list

Bookmark has been removed

Bookmarks list

You can't add any more bookmarks

By registering as a member, you can increase the number of bookmarks you can save and organize them with labels.

Free membership registration
Tohoku University Technology: 1,3-Dioxolane derivative, D-532: T18-094

Tohoku University Technology: 1,3-Dioxolane derivative, D-532: T18-094

Renal functions and tissues in diabetic nephropaty models is improved through D-532 oral administration.

The number of dialysis patients continues to increase, and it is known that applox. 40% of the patients requiring dialysis in Japan were ordinally those with diabetic nephropathy (DN). The treatment for DN is often symptomatic by controling blood sugar and blood pressure, and to date, no effective therapeutic agent for curative treatment has been developed.　 　This invention discloses a 1, 3-dioxolane compounds D-532 and the derivertives thereof, which inhibits the function of the glucose-responsive transcription factor ChREBP (Carbohydrate responsive element binding protein), for DN treatment. 　D-532 was found by ordinally constructed high-throughput screening based on ChREBP reporter assay with applox. 7,000 of compound library in Tohoku University (Fig.1). Synthesized analogs and isomers thereof were also tested and showed inhibitory effect against ChREBP function, although D-532 showed the highest activity (Data not shown). 　The expression of ChREBP target genes were suppressed by D-532 administration for DN animal model (Fig.2). Urinary albumin excretion and blood creatinine were also improved in DN animals with D-532 (Fig.3). Further, the disappearance of foot process in glomerulus, which is often observed in DN kidney, was suppressed (Data not shown), suggesting that D-532 may act directly to renal tissue and show the effects above.

  • others
  • medicine

Added to bookmarks

Bookmarks list

Bookmark has been removed

Bookmarks list

You can't add any more bookmarks

By registering as a member, you can increase the number of bookmarks you can save and organize them with labels.

Free membership registration
Tohoku Univ. Technology：The Treatment and Prevention of Inflammatory Bowel Disease ： T23-033

Tohoku Univ. Technology：The Treatment and Prevention of Inflammatory Bowel Disease ： T23-033

Anti-inflammatory effect by xCT inhibition or Glutamine synthetase inhibition

　The limited number of drugs available for the treatment of inflammatory bowel disease(IBD) and their severe side effects, including immunosuppression, have led to calls for research into drugs without side effects.　 　The inventors focused on the role of xCT, a cystine/glutamate antiporter, in IBD. Their research suggests that xCT inhibitors or glutamine synthetase inhibitors may be therapeutic/preventive agents for inflammatory diseases. [RESULTS] ・Mice with intestinal epithelium-specific xCT deficiency showed anti-inflammatory effects on dextran sulfate sodium(DSS) colitis(Fig.1). ・Glutamine synthetase inhibitor (MSO：Methionine sulfoximine) showed anti-inflammatory effects on DSS colitis(Fig.2).

  • others
  • medicine

Added to bookmarks

Bookmarks list

Bookmark has been removed

Bookmarks list

You can't add any more bookmarks

By registering as a member, you can increase the number of bookmarks you can save and organize them with labels.

Free membership registration
Tohoku Univ. Technology：A novel therapeutic target Vasohibin-2: T18-447_T12-072

Tohoku Univ. Technology：A novel therapeutic target Vasohibin-2: T18-447_T12-072

For the treatment of refractory cancers including pancreatic cancer

Vasohibin-2 (referred to as VASH2) knockdown significantly reduced metastasis of pancreatic cancer cells (Fig. 1) and prolonged survival period after orthotopic transplantation (Fig.2). The mechanisms of action are;　 (1)VASH2 knockdown reduces cancer cell invasion through suppressing of tubulin carboxypeptidase activity within the cell. (2) VASH2 secreted by cancer cells stimulates tumor angiogenesis, so when VASH2 was knocked down, tumor angiogenesis was prevented. (3) VASH2 regulates the production of inflammatory chemokines and cytokines in cancer cells, which in turn, accelerates the recruitment of MDSC and TAM and prevents the infiltration of cytotoxic T lymphocytes. The inhibition of VASH2 eliminates immune suppression in pancreatic cancer.

  • others
  • medicine

Added to bookmarks

Bookmarks list

Bookmark has been removed

Bookmarks list

You can't add any more bookmarks

By registering as a member, you can increase the number of bookmarks you can save and organize them with labels.

Free membership registration
Tohoku Univ. Technology ：Lubiprostone, a constipation drug, has a kidney protective effect：T25-005

Tohoku Univ. Technology ：Lubiprostone, a constipation drug, has a kidney protective effect：T25-005

Improvement of Intestinal Microbiota Improves Mitochondrial Function

Chronic kidney disease (CKD) is a major global health issue without any drugs that improve kidney function. Previous mouse experiments showed that lubiprostone, a constipation drug, reduces uremic toxin accumulation by improving the intestinal environment altered by kidney decline, thus inhibiting kidney damage progression 1. A phase II clinical trial was conducted to test lubiprostone's effects on kidney function in patients. Results revealed dose-dependent suppression of kidney function decline (eGFR) in lubiprostone-treated patients compared to placebo. Further analysis showed lubiprostone improves kidney mitochondrial function by modulating the gut microbiota and increasing spermidine production, which enhances mitochondrial activity and provides kidney protection.

  • others
  • medicine

Added to bookmarks

Bookmarks list

Bookmark has been removed

Bookmarks list

You can't add any more bookmarks

By registering as a member, you can increase the number of bookmarks you can save and organize them with labels.

Free membership registration
Non-explosive, low-vibration steam pressure crushing agent 'Gunsizer'

Non-explosive, low-vibration steam pressure crushing agent 'Gunsizer'

Contributes to shortening construction time, enhancing safety, and reducing costs! Usable even in situations where work with explosives is not possible. Suppresses shock waves, taking into consideration nearby houses and structures.

The "Gansizer" is a crushing agent that clears the constraints of vibration and noise related to environmental conservation around work sites, achieving efficient crushing through steam pressure. It crushes brittle materials such as rock formations, stones, and concrete structures instantly in a low-vibration state using the steam pressure generated during the thermal decomposition of the agent. Although the crushing procedure is similar to blasting methods, the use of this crushing agent is not subject to the Explosives Control Law. This product enables safe, speedy, and low-cost crushing operations within the construction period. 【Features】 ■ Instant crushing capability ■ Shortened construction period and cost reduction ■ No need for consumption permit notifications due to being non-explosive ■ No waiting time required like static crushing agents ■ Low vibration due to the absence of shock waves ■ Registered in the Ministry of Land, Infrastructure, Transport and Tourism's New Technology Information System (NETIS) It is being used in recovery and reconstruction work following the Great East Japan Earthquake! (Can also be used underwater) *For more details, please refer to the PDF materials or feel free to contact us.

  • Safety Supplies
  • Safety and consumables
  • medicine

Added to bookmarks

Bookmarks list

Bookmark has been removed

Bookmarks list

You can't add any more bookmarks

By registering as a member, you can increase the number of bookmarks you can save and organize them with labels.

Free membership registration
Do you feel down in winter? It's called "winter blues"!

Do you feel down in winter? It's called "winter blues"!

Thorough explanation of causes and countermeasures!

As it gets cold during this time of year, some people may find themselves feeling down, saying things like "I just feel gloomy" or "I have no motivation to do anything..." This might be what is known as "winter blues." It has symptoms similar to depression and is more likely to occur in winter, which is why it is also called "seasonal affective disorder." In this article, we will explain in detail the symptoms, causes, and ways to improve "winter blues." *The continuation of the article can be viewed through the related link (our company website).

  • others
  • medicine

Added to bookmarks

Bookmarks list

Bookmark has been removed

Bookmarks list

You can't add any more bookmarks

By registering as a member, you can increase the number of bookmarks you can save and organize them with labels.

Free membership registration
Market Research Report on Chronic Obstructive Pulmonary Disease (COPD) Treatment Drugs Worldwide

Market Research Report on Chronic Obstructive Pulmonary Disease (COPD) Treatment Drugs Worldwide

Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Drug Market 2022-2031: Industry Analysis, Size, Share, Growth, Trends, Forecast

The market research report by Transparency Market Research examines and analyzes the global market for chronic obstructive pulmonary disease (COPD) treatments, organizing content such as the introduction, assumptions and research methods, executive summary, market overview, key insights, analysis by drug class (combination therapy, bronchodilators, corticosteroids, phosphodiesterase type 4 inhibitors, and others), analysis by type (chronic bronchitis, emphysema), analysis by distribution channel (hospital pharmacies, retail pharmacies, online pharmacies), regional analysis (North America, Europe, Asia-Pacific, Latin America, Middle East and Africa), and competitive landscape.

  • others
  • medicine

Added to bookmarks

Bookmarks list

Bookmark has been removed

Bookmarks list

You can't add any more bookmarks

By registering as a member, you can increase the number of bookmarks you can save and organize them with labels.

Free membership registration
World Cervical Cancer Treatment Drug Market Research Report (～2027)

World Cervical Cancer Treatment Drug Market Research Report (～2027)

Global Market for Cervical Cancer Treatment Drugs (up to 2027): By Disease, By Treatment Type, By End User, By Region

The market research report by 360iResearch predicts that the global cervical cancer treatment market will grow from $6,920.92 million in June 2021 to $7,263.09 million in 2022, and further increase at an average annual rate of 5.12% to reach $9,338.97 million by 2027. This report provides a comprehensive analysis of the global cervical cancer treatment market, including an introduction, research methodology, executive summary, market overview, market insights, analysis by disease stage (advanced invasive stage, early invasive stage, pre-malignant lesions), analysis by treatment type (chemotherapy, cold knife conization, conization, cryotherapy, hormone therapy), analysis by end-user (diagnostic centers, hospitals, palliative care clinics, pharmacies), regional analysis (North and South America, United States, Canada, Brazil, Asia-Pacific, Japan, China, India, South Korea, Taiwan, Europe/Middle East/Africa, United Kingdom, Germany, France, Russia, and others), competitive landscape, company information, and more.

  • others
  • medicine

Added to bookmarks

Bookmarks list

Bookmark has been removed

Bookmarks list

You can't add any more bookmarks

By registering as a member, you can increase the number of bookmarks you can save and organize them with labels.

Free membership registration
World Premature Ejaculation Treatment Market Research Report (up to 2027)

World Premature Ejaculation Treatment Market Research Report (up to 2027)

Global Premature Ejaculation Treatment Market (up to 2027): By Drug Type, By Type, By Dosage Form, By Distribution Channel, By Region

The market research report by 360iResearch predicts that the global premature ejaculation treatment market will grow from $2,931.87 million in 2021 to $3,211.16 million in 2022, and further increase at an average annual rate of 9.70% to reach $5,110.43 million by 2027. This report provides a comprehensive analysis of the global premature ejaculation treatment market, including sections on introduction, research methodology, executive summary, market overview, market insights, analysis by drug type (dapoxetine, phosphodiesterase type 5 (PDE5) inhibitors, selective serotonin reuptake inhibitors (SSRIs), local anesthetics, ziltampy), analysis by type (oral medications, topical medications), analysis by dosage form (tablets, sprays), analysis by distribution channel (hospitals, online pharmacies, retail pharmacies), regional analysis (North and South America, United States, Canada, Brazil, Asia Pacific, Japan, China, India, South Korea, Taiwan, Europe/Middle East/Africa, United Kingdom, Germany, France, Russia, and others), competitive landscape, and company information.

  • others
  • medicine

Added to bookmarks

Bookmarks list

Bookmark has been removed

Bookmarks list

You can't add any more bookmarks

By registering as a member, you can increase the number of bookmarks you can save and organize them with labels.

Free membership registration
World Anticoagulant Market Research Report 2022-2031

World Anticoagulant Market Research Report 2022-2031

Global Market for Anticoagulant Antagonists 2022-2031: Industry Analysis, Size, Share, Growth, Trends, Forecast

The research report by Trensperancy Market Research comprehensively investigates and analyzes the global anticoagulant market, including an introduction, assumptions and research methods, executive summary, market overview, key insights, product analysis (prothrombin complex concentrates, vitamin K, protamine, tranexamic acid, and others), distribution channel analysis (hospital pharmacies, retail pharmacies, and others), regional analysis (North America, Europe, Asia-Pacific, Latin America, Middle East and Africa), and competitive landscape.

  • others
  • medicine

Added to bookmarks

Bookmarks list

Bookmark has been removed

Bookmarks list

You can't add any more bookmarks

By registering as a member, you can increase the number of bookmarks you can save and organize them with labels.

Free membership registration
World Premenstrual Syndrome (PMS) Treatment Market Research Report 2022-2031

World Premenstrual Syndrome (PMS) Treatment Market Research Report 2022-2031

Global Market for Premenstrual Syndrome (PMS) Treatment 2022-2031: Industry Analysis, Size, Share, Growth, Trends, Forecast

The research report by Trensperancy Market Research comprehensively investigates and analyzes the global premenstrual syndrome (PMS) treatment market, including an introduction, assumptions and research methods, executive summary, market overview, key insights, analysis by drug type (antidepressants, diuretics, analgesics, oral contraceptives & ovarian suppressants, and others), analysis by sales channel (retail pharmacies, e-commerce, and others), regional analysis (North America, Europe, Asia-Pacific, Latin America, Middle East & Africa), and competitive landscape.

  • others
  • medicine

Added to bookmarks

Bookmarks list

Bookmark has been removed

Bookmarks list

You can't add any more bookmarks

By registering as a member, you can increase the number of bookmarks you can save and organize them with labels.

Free membership registration
World Anti-Obesity Drug Market Research Report (up to 2027)

World Anti-Obesity Drug Market Research Report (up to 2027)

Global Anti-Obesity Drug Market (up to 2027): By Drug Type, Mechanism of Action, and Region

The market research report by 360iResearch predicts that the global anti-obesity drug market size will grow from $3,374.55 million in 2021 to $3,596.69 million in 2022, and further increase at an average annual rate of 6.75% to reach $4,996.46 million by 2027. This report provides a comprehensive analysis of the global anti-obesity drug market, including sections on introduction, research methodology, executive summary, market overview, market insights, analysis by drug type (OTC drugs, prescription drugs), analysis by mechanism of action (central acting drugs, peripheral acting drugs), regional analysis (North and South America, United States, Canada, Brazil, Asia-Pacific, Japan, China, India, South Korea, Taiwan, Europe/Middle East/Africa, United Kingdom, Germany, France, Russia, and others), competitive landscape, and company information.

  • others
  • medicine

Added to bookmarks

Bookmarks list

Bookmark has been removed

Bookmarks list

You can't add any more bookmarks

By registering as a member, you can increase the number of bookmarks you can save and organize them with labels.

Free membership registration
World Animal Drug Formulation Market Research Report 2022-2031

World Animal Drug Formulation Market Research Report 2022-2031

Global Animal Drug Compounding Market 2022-2031: Industry Analysis, Size, Share, Growth, Trends, Forecast

The market research report by Transparency Market Research examines and analyzes the global animal drug formulation market, including an introduction, assumptions and research methods, executive summary, market overview, key insights, product analysis (antimicrobials, anti-inflammatory drugs, central nervous system drugs, gastrointestinal drugs, and others), analysis by animal type (companion animals and livestock), analysis by dosage form (capsules, solutions, powders, suspensions, and others), analysis by route of administration (oral, injectable, topical, rectal, and ophthalmic), regional analysis (North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa), and competitive landscape.

  • others
  • medicine

Added to bookmarks

Bookmarks list

Bookmark has been removed

Bookmarks list

You can't add any more bookmarks

By registering as a member, you can increase the number of bookmarks you can save and organize them with labels.

Free membership registration
World Antiviral Drug Market Research Report (up to 2027)

World Antiviral Drug Market Research Report (up to 2027)

Global Antiviral Drug Market (up to 2027): By Drug Type, By Treatment Method, By Distribution, By Region

The market research report by 360iResearch forecasts that the global antiviral drug market size will grow from $63.96 billion in 2021 to $69.54 billion in 2022, and further increase at an average annual rate of 8.49% to reach $104.33 billion by 2027. This report provides a comprehensive analysis of the global antiviral drug market, including sections on introduction, research methodology, executive summary, market overview, market insights, drug-specific analysis (hepatitis antiviral drugs, herpes antiviral drugs, HIV antiviral drugs, influenza antiviral drugs), treatment method analysis (DNA polymerase inhibitors, neuraminidase inhibitors, protease inhibitors, reverse transcriptase inhibitors), distribution analysis (hospital pharmacies, independent pharmacies & drugstores, online pharmacies), regional analysis (North and South America, the United States, Canada, Brazil, Asia-Pacific, Japan, China, India, South Korea, Taiwan, Europe/Middle East/Africa, the United Kingdom, Germany, France, Russia, and others), competitive landscape, and company information.

  • others
  • medicine

Added to bookmarks

Bookmarks list

Bookmark has been removed

Bookmarks list

You can't add any more bookmarks

By registering as a member, you can increase the number of bookmarks you can save and organize them with labels.

Free membership registration
Global Prostate Cancer Treatment Drug Market Research Report (up to 2027)

Global Prostate Cancer Treatment Drug Market Research Report (up to 2027)

Global Prostate Cancer Treatment Drug Market (up to 2027): By Drug Classification, Distribution Channel, and Region

The market research report by 360iResearch forecasts that the global prostate cancer treatment market will grow from $8,885.84 million in 2021 to $9,422.47 million in 2022, and further increase at an average annual rate of 6.21% to reach $12,759.77 million by 2027. This report provides a comprehensive analysis of the global prostate cancer treatment market, including sections on introduction, research methodology, executive summary, market overview, market insights, analysis by drug classification (chemotherapy, hormone therapy, immunotherapy, targeted therapy), analysis by distribution channel (drugstores & retail pharmacies, hospital pharmacies, online pharmacies), regional analysis (North and South America, United States, Canada, Brazil, Asia-Pacific, Japan, China, India, South Korea, Taiwan, Europe/Middle East/Africa, United Kingdom, Germany, France, Russia, and others), competitive landscape, and company information.

  • others
  • medicine

Added to bookmarks

Bookmarks list

Bookmark has been removed

Bookmarks list

You can't add any more bookmarks

By registering as a member, you can increase the number of bookmarks you can save and organize them with labels.

Free membership registration
Market Research Report on Gout Treatment Drugs Worldwide 2022-2031

Market Research Report on Gout Treatment Drugs Worldwide 2022-2031

Global Market for Gout Treatment Drugs 2022-2031: Industry Analysis, Size, Share, Growth, Trends, Forecast

The research report by Trensperancy Market Research comprehensively investigates and analyzes the global gout treatment drug market, including an introduction, assumptions and research methods, executive summary, market overview, key insights, analysis by drug type (NSAIDs, colchicine, corticosteroids, urate-lowering agents, biologics), analysis by distribution channel (hospital pharmacies, retail pharmacies, online pharmacies), regional analysis (North America, Europe, Asia-Pacific, Latin America, Middle East and Africa), and competitive landscape.

  • others
  • medicine

Added to bookmarks

Bookmarks list

Bookmark has been removed

Bookmarks list

You can't add any more bookmarks

By registering as a member, you can increase the number of bookmarks you can save and organize them with labels.

Free membership registration
World Macular Degeneration Treatment Market Research Report 2022-2031

World Macular Degeneration Treatment Market Research Report 2022-2031

Global Market for Macular Degeneration Treatment 2022-2031: Industry Analysis, Size, Share, Growth, Trends, Forecast

The research report by Transparency Market Research comprehensively investigates and analyzes the global age-related macular degeneration treatment market, including an introduction, assumptions and research methods, executive summary, market overview, key insights, analysis by disease type (wet age-related macular degeneration, dry age-related macular degeneration, others), analysis by drug classification (anti-vascular endothelial growth factor, others), analysis by distribution channel (hospitals, ophthalmology clinics, outpatient surgery centers), regional analysis (North America, Europe, Asia-Pacific, Latin America, Middle East & Africa), and competitive landscape.

  • others
  • medicine

Added to bookmarks

Bookmarks list

Bookmark has been removed

Bookmarks list

You can't add any more bookmarks

By registering as a member, you can increase the number of bookmarks you can save and organize them with labels.

Free membership registration
Global GLP-1 Receptor Agonist Market Research Report (up to 2027)

Global GLP-1 Receptor Agonist Market Research Report (up to 2027)

Global GLP-1 Receptor Agonist Market (up to 2027): By Product, Drug Class, Route of Administration, Application, Distribution Channel, and Region

The market research report by 360iResearch forecasts that the global GLP-1 receptor agonist market size will grow from $3,632.28 million in 2021 to $4,016.94 million in 2022, and further increase at an average annual rate of 10.84% to reach $6,737.14 million by 2027. This report provides a comprehensive analysis of the global GLP-1 receptor agonist market, including sections on introduction, research methodology, executive summary, market overview, market insights, product analysis (including Bidurian, Ozempic, Saxenda, Trulicity, and Victoza), drug classification analysis (including Albiglutide, Dulaglutide, Exenatide, Liraglutide, and Lixisenatide), route of administration analysis (oral and non-oral), application analysis (including liver cirrhosis, non-alcoholic fatty liver disease, obesity, and type 2 diabetes), regional analysis (including North and South America, the United States, Canada, Brazil, Asia-Pacific, Japan, China, India, South Korea, Taiwan, Europe/Middle East/Africa, the United Kingdom, Germany, France, Russia, and others), competitive landscape, and company information.

  • others
  • medicine

Added to bookmarks

Bookmarks list

Bookmark has been removed

Bookmarks list

You can't add any more bookmarks

By registering as a member, you can increase the number of bookmarks you can save and organize them with labels.

Free membership registration
Market Research Report on the Global Animal Antimicrobial Drug Market (up to 2027)

Market Research Report on the Global Animal Antimicrobial Drug Market (up to 2027)

Global Animal Antimicrobial Market (up to 2027): By Animal Type, Product Type, Route of Administration, Distribution Channel, and Region

360iResearch predicts that the global market size for veterinary anti-infective drugs, which was $3,098.06 million in 2021, will expand to $3,448.14 million in 2022 and then grow at a CAGR of 11.55% to reach $5,970.67 million by 2027. This report provides a comprehensive analysis of the global market for veterinary anti-infective drugs, including sections on introduction, research methodology, executive summary, market overview, market insights, analysis by animal type (companion animals, livestock), analysis by product type (antibiotics, antifungals, antivirals), analysis by route of administration (injectables, oral medications), analysis by distribution channel (e-commerce, retail pharmacies, veterinary clinics), regional analysis (North and South America, the United States, Canada, Brazil, Asia-Pacific, Japan, China, India, South Korea, Taiwan, Europe/Middle East/Africa, the United Kingdom, Germany, France, Russia, and others), competitive landscape, and company information.

  • others
  • medicine

Added to bookmarks

Bookmarks list

Bookmark has been removed

Bookmarks list

You can't add any more bookmarks

By registering as a member, you can increase the number of bookmarks you can save and organize them with labels.

Free membership registration

Search Keywords Related to medicine

COPYRIGHT © 2001-2026 IPROS CORPORATION ALL RIGHTS RESERVED.